Rationale and design of ARTS: a randomized, double‐blind study of BAY 94‐8862 in patients with chronic heart failure and mild or moderate chronic kidney disease by Pitt, Bertram et al.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Rationale and design of ARTS: a randomized,
double-blind study of BAY 94-8862 in patients
with chronic heart failure and mild or moderate
chronic kidney disease
Bertram Pitt1*, Gerasimos Filippatos2, Mihai Gheorghiade3, Lars Kober4,
Henry Krum5, Piotr Ponikowski6, Christina Nowack7, Peter Kolkhof8,
So-Young Kim9, and Faiez Zannad10
1University of Michigan School of Medicine, Ann Arbor, MI 48109-0366, USA; 2Heart Failure Unit, Department of Cardiology, Attikon University Hospital, Athens, Greece; 3Center
for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 4Heart Centre, Rigshospitalet, University of Copenhagen, Denmark;
5Department of Epidemiology and Preventive Medicine, Centre of Cardiovascular Research and Education in Therapeutics, Monash University, Melbourne, VIC, Australia; 6Medical
University, Clinical Military Hospital, Wroclaw, Poland; 7Global Clinical Development, Bayer Pharma AG, Wuppertal, Germany; 8Cardiology Research, Department of Heart
Diseases, Global Drug Discovery, Bayer HealthCare Pharmaceuticals, Wuppertal, Germany; 9Bayer Vital GmbH, Bayer HealthCare, Leverkusen, Germany; and 10INSERM, Centre
for Clinical Investigation 9501 and Unit 961, Central University Hospital and the Department of Cardiology, Université de Lorraine, Nancy, France
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Aims BAY 94-8862 is a novel, non-steroidal, mineralocorticoid receptor antagonist with greater selectivity than spirono-
lactone and stronger mineralocorticoid receptor binding affinity than eplerenone. The aims of the MinerAlocorticoid
Receptor Antagonist Tolerability Study (ARTS; NCT01345656) are to evaluate the safety and tolerability of BAY 94-
8862 in patients with heart failure associated with a reduced left ventricular ejection fraction (HFREF) and chronic
kidney disease (CKD), and to examine the effects on biomarkers of cardiac and renal function.
Methods ARTS is a multicentre, randomized, double-blind, placebo-controlled, parallel-group study divided into two parts. In
part A, oral BAY 94-8862 [2.5, 5, or 10 mg once daily (o.d.)] is compared with placebo in 60 patients with HFREF
and mild CKD. Outcome measures include serum potassium concentration, biomarkers of renal injury, estimated
glomerular filtration rate (eGFR), and albuminuria. Part B compares BAY 94-8862 (2.5, 5, or 10 mg o.d., or 5 mg
twice daily), placebo, and open-label spironolactone (25–50 mg o.d.) in 360 patients with HFREF and moderate
CKD. Outcome measures include the change in serum potassium concentration with BAY 94-8862 vs. placebo
(primary endpoint) and vs. spironolactone, safety and tolerability, biomarkers of cardiac and renal function or
injury, eGFR, and albuminuria. BAY 94-8862 pharmacokinetics are also assessed.
Perspectives ARTS is the first phase II clinical trial of BAY 94-8862 and is expected to provide a wealth of information on BAY 94-
8862 in patients with HFREF and CKD, including the optimal dose range for further studies.
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Introduction
In patients hospitalized for heart failure (HF), high levels of aldos-
terone are an important predictor of early re-hospitalization.1,2
The effects of aldosterone are mediated via activation of its specific
nuclear hormone receptor, the mineralocorticoid receptor (MR).
Mineralocorticoid receptor antagonists (MRAs) have been found
to be effective in reducing total mortality as well as frequency of
hospitalizations for HF in: patients with chronic HF associated
with a reduced left ventricular ejection fraction (HFREF); patients
with HFREF following myocardial infarction; and patients with
mild symptoms of HFREF.2– 5 MRAs have also been shown to
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lower blood pressure in patients with primary aldosteronism and
individuals with essential hypertension, especially in those with re-
sistant hypertension.6,7 Several studies have demonstrated that
addition of an MRA to conventional therapy [an angiotensin-
converting enzyme (ACE) inhibitor and/or an angiotensin receptor
blocker (ARB)] in patients with chronic kidney disease (CKD) sub-
stantially reduces proteinuria compared with conventional therapy
alone.8 –11 Reductions in markers of myocardial fibrosis have also
been observed in patients receiving MRAs in combination with
ACE inhibitors or ARBs.12
However, the use of MRAs in eligible patients remains subopti-
mal.13–15 The reluctance of some clinicians to use the available
MRAs, spironolactone and eplerenone, in HFREF despite their
proven effects on mortality is largely attributable to their fear of
inducing hyperkalaemia, especially in patients with concomitant
diabetes mellitus and/or CKD. The use of spironolactone (a first-
generation MRA) is also limited by significant progestogenic and
antiandrogenic activity owing to its structural similarity to proges-
terone;16,17 this activity has been associated with the occurrence of
breast pain in both sexes, gynaecomastia and impotence in males,
and menstrual irregularities in females.4,18 Eplerenone (a second-
generation MRA) is more specific for the MR than spironolactone,
but the results of two head-to-head comparator studies in patients
with hypertension suggest that eplerenone may have reduced anti-
hypertensive efficacy compared with spironolactone.19,20
These limitations of spironolactone and eplerenone have stimu-
lated further research, leading to the discovery of new non-steroidal
MRAs that are more selective for the MR than spironolactone and
have greater affinity for the MR than eplerenone.21,22 To reduce
the risk of hyperkalaemia, a next-generation MRA is needed that
has more pronounced cardiac activity in comparison with the avail-
able steroidal MRAs, so that improvements in cardiac function can
be achieved without deleterious changes to sodium–potassium
homeostasis in the kidney. Such a compound could result in
MRAs being used in a larger number of patients with HF and
CKD, as well as in other indications such as acute HF syndromes,23
thereby potentially reducing cardiovascular mortality, hospitaliza-
tions for HF, and healthcare resource use.
BAY 94-8862 is a novel, non-steroidal, next-generation MRA.22
In vitro studies indicate that BAY 94-8862 has superior selectivity
compared with spironolactone and improved affinity for the MR
compared with eplerenone (Table 1). The safety and tolerability
of different oral doses of BAY 94-8862 have been assessed and
confirmed in healthy volunteers (data on file). We report the
design of the MinerAlocorticoid Receptor Antagonist Tolerability
Study (ARTS), the first phase II clinical trial of BAY 94-8862. The
study has been initiated to evaluate the safety and tolerability of dif-
ferent oral doses of BAY 94-8862 in patients with HFREF and
CKD, and to examine its effect on biomarkers of cardiac and
renal function or injury.
Methods
Study design
ARTS (ClinicalTrials.gov identifier: NCT01345656) is a multicentre,
randomized, double-blind, placebo-controlled, parallel-group study
divided into two parts: part A was conducted in patients with
HFREF and mild CKD [estimated glomerular filtration rate (eGFR)
60 to ,90 mL/min/1.73 m2), and part B is currently being conducted
in patients with HFREF and moderate CKD (eGFR 30–60 mL/min/
1.73 m2). Part B has an open-label active comparator (spironolactone)
group in addition to the placebo control group (Figure 1).
Objectives
The objective of part A was to investigate the safety, tolerability, and
renal effects of oral BAY 94-8862 compared with placebo. The
effects of BAY 94-8862 on serum potassium concentration, biomar-
kers of renal injury, eGFR [calculated using the Modification of Diet
in Renal Disease (MDRD) formula],24 and albuminuria were assessed,
as well as the pharmacokinetics of BAY 94-8862 and its metabolites in
plasma after multiple oral doses.
The primary objective of part B is to investigate the change in serum
potassium concentration after treatment with oral BAY 94-8862 com-
pared with placebo. Secondary objectives are to compare the change
in serum potassium concentration in the BAY 94-8862 and spironolac-
tone groups, to assess safety and tolerability of BAY 94-8862, and to
examine the effects of BAY 94-8862 on biomarkers of cardiac and
renal function or injury, eGFR (MDRD), and albuminuria. In addition,
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Table 1 In vitro potency and selectivity of spironolactone, eplerenone, and BAY 94-8862 in functional cell-based steroid
hormone receptor transactivation assays25,26
Spironolactone Eplerenone BAY 94-8862
Mineralocorticoid receptor IC50 (nM) 24.2 990 17.8
Glucocorticoid receptor IC50 (nM) 2410 ≥21 980 ≥10 000
Androgen receptor IC50 (nM) 77.1 ≥21 240 ≥10 000
Progesterone receptor IC50/EC50
a (nM) 740a ≥31 210 ≥10 000
Oestrogen receptor a IC50 (nM) 5970 ≥30 000 ≥10 000
Oestrogen receptor b IC50 (nM) 4940 ≥30 000 ≥10 000
Values were determined using Chinese hamster ovary (CHO)-K1 cells stably expressing the ligand-binding domains of the oxo-steroid receptors. Data were obtained from at least
four independent experiments performed in duplicate, except for the oestrogen receptor data, which were obtained from two independent experiments. The respective steroid
hormone cell lines and assay procedures have been described previously.25
EC50, half-maximal effective concentration; IC50, half-maximal inhibitory concentration.
aSpironolactone is an agonist of the progesterone receptor and the respective EC50 value is therefore given.
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the pharmacokinetics of BAY 94-8862 in plasma after multiple oral
doses will be assessed.
Patients
Adult males and females without childbearing potential with a clinical
diagnosis of HFREF [New York Heart Association (NYHA) class II–
III], treated with evidence-based therapy for HFREF, and who
meet all of the inclusion criteria and none of the exclusion criteria
(Table 2) will be eligible for enrolment in the study.
Patients must be withdrawn from the study if: they decline to partici-
pate further; continuation of the study would be harmful to the
patient’s well-being in the opinion of the investigator; it is specifically
requested by the sponsor; overall study drug intake is , 80% or
.120% of the prescribed dose; any adverse event (AE) occurs that
is not acceptable in the opinion of the investigator and/or patient; or
the patient develops worsening cardiac function that requires hospital-
ization and initiation of intravenous drug treatment. In addition, if
serum potassium is between 5.5 and 6.0 mmol/L, a second blood
sample must be taken as soon as possible, at the latest on the next
day. If serum potassium is still . 5.5 mmol/L in the second sample,
the study drug must be discontinued permanently. If serum potassium
is . 6.0 mmol/L in any blood sample, the study drug must be discon-
tinued permanently without any further laboratory assessment.
Study medication
BAY 94-8862 is administered as oral, immediate-release tablets. In
both parts of the study, eligible patients are randomized in the
14 days following a screening visit, and receive the study drug for
4 weeks. In part A, eligible patients were randomized 1:1:1:1 to
receive BAY 94-8862 at 2.5, 5, or 10 mg once daily (o.d.) or
placebo. In part B, eligible patients are randomized 1:1:1:1:1:1 to
receive BAY 94-8862 at 2.5, 5, or 10 mg o.d., BAY 94-8862 at 5 mg
twice daily (b.d.), placebo, or open-label spironolactone (initial dose
25 mg o.d. up-titrated to 50 mg o.d. on day 15+1 if the serum potas-
sium concentration is ≤ 4.8 mmol/L). There is no crossover of patients
between part A and part B of the study.
Treatment with evidence-based therapy for HFREF is a requirement
for inclusion in the study (Table 2) and may be continued during the
course of the study, apart from the exceptions noted below. Concomi-
tant medications not allowed during the study (from initiation of study
drug treatment until the follow-up visit has been completed) include:
any aldosterone antagonist or renin inhibitor; use of an ACE inhibitor
with an ARB; potassium-sparing agents such as potassium-sparing
diuretics; high-dose acetylsalicylic acid (.500 mg/day); daily treatment
with non-steroidal anti-inflammatory agents; potent cytochrome P450
(CYP) isoenzyme 3A4 inhibitors or inducers; and strong CYP2C8
inhibitors such as gemfibrozil.
Investigations
Participating patients are assessed at the screening visit, at baseline/day
1 (start of study drug administration), day 4+ 1, day 8+1, and weekly
thereafter until the end of the study. A follow-up visit will be scheduled
14 days after the last intake of study medication. Patients who discon-
tinue the study prematurely are also assessed as soon as possible after
discontinuation. In part B, patients receiving spironolactone at the
up-titrated dose of 50 mg o.d. are assessed at an additional visit on
day 18+1.
Details of the assessments made at each visit are shown in
Table 3. Briefly, patients undergo a physical examination at the
screening visit, and demographic data and the medical history are
also recorded. Continuous assessment of AEs starts immediately
Figure 1 Study flow charts. The study enrols patients with chronic heart failure with left ventricular systolic dysfunction and mild (part A) or
moderate (part B) chronic kidney disease [mild, estimated glomerular filtration rate (eGFR) 60 to ,90 mL/min/1.73 m2; moderate, eGFR
30–60 mL/min/1.73 m2]. There is no crossover of patients between part A and part B of the study. b.d., twice daily; o.d., once daily.
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after signing the informed consent form until the follow-up visit or
the premature discontinuation visit (if applicable). For each AE, the
investigator records the maximum intensity (mild, moderate, or
severe), seriousness, relationship to the study drug, any actions
taken, and the final outcome. At intervals during the course of the
study, concomitant medications are noted and vital signs (heart
rate and blood pressure) and 12-lead electrocardiograms (ECGs)
are assessed after resting for at least 10 min.
Table 2 Inclusion and exclusion criteria
Inclusion criteria
† Written informed consent signed before any study-specific procedure
† Men aged ≥18 years or post-menopausal women aged ≥55 years or women aged ≥18 years not of childbearing potential based on surgical treatment
such as bilateral tubal ligation, bilateral ovarectomy, or hysterectomy
† Clinical diagnosis of chronic heart failure, either ischaemic or non-ischaemic, NYHA class II– III for at least 3 monthsa
† Treated with evidenced-based therapy for chronic heart failure with LVSD (e.g. beta-blockers and ACE inhibitors or ARBs, as well as diuretics, unless
contraindicated or not tolerated)
† Stable patients (NYHA class II– III) naı̈ve to aldosterone antagonist therapy and stable, low-risk patients (NYHA class II) with ongoing aldosterone
antagonist therapy that, in the opinion of the investigator, may be safely withdrawn for the duration of the study (maximum 10 weeks)
† A record of LVEF ≤40% (measured by any modality) in the patient’s medical history without intervening revascularization, cardiac surgery, or
implantation of biventricular pacemaker in the meantime; for those patients with cardiac intervention, LVEF must be re-assessed and an LVEF ≤40%
re-confirmed after the cardiac intervention
† Known kidney damage for ≥3 months, as defined by structural or functional abnormalities of the kidney, and:
† part A: eGFR 60 to ,90 mL/min/1.73 m2 (MDRD) at screening visit
† part B: eGFR 30–60 mL/min/1.73 m2 (MDRD) at screening visit
† Serum potassium ≤4.8 mmol/L at screening visit
† Systolic blood pressure ≥90 mmHg without signs or symptoms of hypotension at screening visit
† Ability to understand and follow study-related instructions
Exclusion criteria
† Women of childbearing potential
† Known hypersensitivity to the study drug (active substance or excipients) or spironolactone and respective excipients (part B only)
† Patients with anuria, acute renal failure, or Addison’s disease
† Worsening heart failure requiring hospitalization and treatment with intravenous diuretics in the 30 days before the screening visit for patients (NYHA
class II– III) naı̈ve to aldosterone antagonist therapy or in the 6 months before the screening visit for patients (NYHA class II) who, immediately before
study entry, are receiving aldosterone antagonist therapy
† Acute coronary syndrome or unstable coronary artery disease in the 30 days before randomization
† Valvular heart disease requiring surgical intervention during the course of the study
† Evidence of increased ventricular vulnerability (e.g. survived ventricular fibrillation, sustained ventricular tachycardia, or firing of implantable
cardioverter-defibrillator in the 30 days before randomization) requiring any intervention during the course of the study
† History of hospitalization for hyperkalaemia or acute renal failure induced by previous aldosterone antagonist treatment
† History of or clinically significant evidence of any severe disease other than chronic heart failure that would preclude participation in the study
† Patients with clinically relevant hepatic dysfunction at screening visit indicated by one of the following: total bilirubin concentration more than twice the
ULN and alanine aminotransferase levels more than three times the ULN or hepatic insufficiency classified as Child–Pugh B or C
† Use of any renin inhibitor or aldosterone antagonist in the 30 days before randomization
† Concomitant therapy with potassium-sparing agents, high-dose acetylsalicylic acid (.500 mg/day), or continuous treatment with non-steroidal
anti-inflammatory agents
† Concomitant therapy with potent CYP isoenzyme 3A4 inhibitors or inducers (to be stopped ≥7 days before randomization) or strong CYP2C8
inhibitors (to be stopped ≥48 h before randomization) such as gemfibrozil (investigators will be provided with a list of concomitant medications
considered potent CYP3A4 inhibitors or inducers or strong CYP2C8 inhibitors)
† Ongoing drug or alcohol abuse
† Concomitant regular liquorice consumption
† Uncontrolled hypertension at the screening visit requiring additional antihypertensive treatment during the course of the study
† Clinically relevant findings from the physical examination that may influence absorption, distribution, metabolism, elimination, or effects of the study
drugs, or jeopardize the patient’s safety during the study
† Poorly controlled diabetes mellitus with glycated haemoglobin .8.5% at screening visit
† Participation in another clinical study or treatment with another investigational product in the 30 days before randomization
† Any other condition or therapy that will make the patient unsuitable for this study and will not allow participation for the full planned study period
† Previous assignment to treatment during this study
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CYP, cytochrome P450; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection
fraction; LVSD, left ventricular systolic dysfunction; MDRD, Modification of Diet in Renal Disease; MRA, mineralocorticoid receptor antagonist; NYHA, New York Heart
Association; ULN, upper limit of the normal range.
aMRA-naı̈ve patients can be considered for participation in this study independently of their NYHA class (II– III) at the screening visit. Interruption of ongoing MRA treatment
should be considered only in patients with NYHA class II, not hospitalized for worsening heart failure in the 6 months before the screening visit, and only if the investigator
considers the patient’s estimated individual risk of a cardiovascular event to be acceptable.
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Blood samples are taken to measure levels of thyroid-stimulating
hormone, free triiodothyronine, and free thyroxine, as well as glycated
haemoglobin (HbA1c), serum creatinine (from which the eGFR is cal-
culated), and cystatin C. Biomarkers indicating renal injury [kidney
injury molecule (KIM)-1 and neutrophil gelatinase-associated lipocalin
(NGAL)] are measured in urine. In part B, levels of biomarkers reflect-
ing cardiac function [brain natriuretic peptide (BNP), N-terminal
proBNP, ultrasensitive troponin I, asymmetric dimethylarginine
(ADMA), osteopontin, galectin-3, and aldosterone] are measured in
blood. Urine samples are taken to measure the urinary creatinine:albu-
min ratio. Standard clinical chemistry tests are also performed.
In addition, blood samples for pharmacokinetic analysis are taken at
pre-specified time points. In each case, the time of study drug intake
and the sampling time will be recorded. The plasma concentrations
of BAY 94-8862 are determined using a sparse sampling approach in
all participants.
Study organization
Data from part A were reviewed for safety and tolerability by an inde-
pendent data monitoring committee (DMC) in August 2011. The
safety and tolerability of different doses in patients with HFREF and
mild CKD were confirmed by the DMC. Part B was started in patients
with HFREF and moderate CKD at the beginning of September 2011.
Statistical considerations
Statistical methodology
There will be four analysis sets: the safety set (all patients who have
taken at least one dose of study drug); the full analysis set (all indivi-
duals from the safety set with baseline and at least one post-baseline
serum potassium values); the per protocol set (all patients from the
full analysis set of part B with valid serum potassium data at visit 6
or 7 and no major protocol deviations); and the pharmacokinetic ana-
lysis set (all patients who complete the study without major protocol
deviations). In part A, all variables will be analysed descriptively in the
safety set. In part B, the primary analysis will be performed in the full
analysis set, with a supportive analysis in the per protocol set.
The primary safety variable in part B will be the change in mean
serum potassium values from baseline at visits 6 and 7. Five different
dose–response models [linear, quadratic, exponential, logistic, or
maximum effect (Emax)] will be fitted to the serum potassium data
from the placebo and BAY 94-8862 groups, and the best model will
be selected based on the Akaike and Bayesian information criteria.
Based on the selected dose–response model, the 95% confidence
interval (CI) will be constructed, and the BAY 94-8862 dose range
that increases serum potassium concentration more than placebo
but less than spironolactone will be identified. An exploratory statistic-
al comparison will be performed between the BAY 94-8862 dose
groups that are within this range and the spironolactone group.
In addition, changes in biomarkers, eGFR (MDRD formula), albumin-
uria, serum potassium and magnesium concentrations, blood pressure,
and heart rate will be assessed using analysis of covariance. The
numbers of patients with serum potassium concentrations
.5.5 mmol/L and 6.0 mmol/L will be analysed by Fisher’s exact test.
The analyses for the above secondary variables will be performed in
the full analysis set and per protocol analysis set; all other safety ana-
lyses will be performed in the safety set. Based on a sparse sampling
approach performed at multiple visits, the pharmacokinetics of BAY
94-8862 will be analysed using population-pharmacokinetic methods.
Safety laboratory parameters and ECG data will be analysed descrip-
tively only.
Sample size
A normally distributed data set with a common standard deviation of
serum potassium of 0.5 mmol/L (based on literature research) and
mean values that have a linear relationship with the dose was simulated
for a sample size of 60 patients in the placebo group and each BAY
94-8862 treatment group. A linear line was fitted and the 95% CI
was constructed. For the given sample size, the width of the one-sided
95% CI was  0.08 mmol/L.
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Table 3 Schedule of assessment
Visit Screen 1 (Baseline) 2 3 4 5a 6 7 PD 8 (Follow-up)
Day ≤ 214 1 4+ 1 8+ 1 15+ 1 18+ 1 22+ 2 29+ 2 43+ 5
Informed consent X
Assess eligibility X X
Demographic data X
Medical history X
Physical examination X X X X
12-lead ECG X X X X X X X X
Vital signs X X X X X X X X
PK blood samplingb X X X X X X
Haematology X X X X X X X X
Clinical chemistry X X X X X X X X X X
Urinalysis X X X X X X
Blood and urine samples for biomarkers X X X X X
Adverse events X X X X X X X X X X
Concomitant medications X X X X X X X X X X
ECG, electrocardiogram; PD, premature discontinuation; PK, pharmacokinetics.
aVisit 5 is performed only in part B and only in patients who were up-titrated to spironolactone 50 mg once daily at visit 4 (day 15).
bNot applicable to patients on open-label treatment with spironolactone.
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For the exploratory comparison of the BAY 94-8862 dose groups
with the spironolactone group, assuming a common standard deviation
of 0.5 mmol/L for change in serum potassium concentration and 60
patients per group, each comparison will have 80% power to detect
a difference between the BAY 94-8862 dose group and the spironolac-
tone group.
Ethical considerations
The procedures set out in this protocol pertaining to the conduct,
evaluation, and documentation of this study are designed to ensure
that the sponsor and investigator abide by Good Clinical Practice
guidelines and follow the guiding principles detailed in the Declaration
of Helsinki. The study is carried out in keeping with applicable local
law(s) and regulation(s). Documented approval from appropriate
independent ethics committee(s) or institutional review board(s) was
obtained for all participating centres/countries before the start of
the study.
Discussion
In order to avoid or at least diminish the untoward side effect of
hyperkalaemia associated with currently available MRAs, drugs
with a more pronounced cardiac or vascular activity, at least in
comparison with the available steroidal MRAs, are desirable so
that improvements in cardiac function can be achieved without
deleterious changes to sodium–potassium homeostasis in the
kidney. Screening for novel non-steroidal MRAs led to the identi-
fication of dihydropyridine-based compounds such as BR-4628,
which occupies the MR ligand-binding cavity differently from
classical steroidal MRAs.25 A medicinal chemistry optimization pro-
gramme culminated in the identification of BAY 94-8862,26 which is
at least as potent as spironolactone, even more selective than
eplerenone (Table 1), and has no residual L-type calcium channel
blocking activity, in contrast to related dihydropyridine-based
MRAs.26 –28 The physicochemical properties that drive binding to
plasma proteins, tissue permeability, and distribution of this
novel compound may lead to a more favourable balance of
cardiac antiremodelling effects vs. renal (electrolyte) effects
compared with approved MRAs, ultimately leading to an improved
clinical safety profile with a reduced risk of hyperkalaemia.
ARTS has been designed to address several key questions
related to the potential efficacy and safety of BAY 94-8862. The in-
clusion of both a placebo group and a positive control group
treated with spironolactone (25–50 mg o.d.) should allow insight
into the relative effects of BAY 94-8862 on renal function and
the incidence of hyperkalaemia in patients with HFREF and moder-
ate CKD treated with standard therapy (including an ACE inhibitor
or ARB, a beta-blocker, and diuretics), many of whom are
expected to have concomitant diabetes mellitus. The open-label
nature of the spironolactone treatment will have to be considered
when interpreting the results, because investigators may reduce
potassium more in the spironolactone group than in the other
four groups.
It has been suggested that MRAs may have beneficial effects on
the kidneys in patients with CKD. A systematic review of clinical
studies in patients with CKD found that addition of MRAs to stand-
ard therapy led to a reduction in proteinuria compared with
placebo, although a significant improvement in eGFR was not
observed.11 There has not, however, been a large trial powered
to evaluate renal and cardiovascular outcomes in patients with
CKD, due to the fear of inducing serious hyperkalaemia with the
presently available MRAs. A retrospective analysis of almost
25 000 veterans in the USA found that the incidence of hyperka-
laemia (serum potassium .5.5 mmol/L) was more than three
times higher in patients with CKD than in those without CKD, re-
gardless of renin–angiotensin–aldosterone system inhibitor status,
and that there was an increased mortality associated with a serum
potassium concentration . 5.5 mmol/L within 24 h of its occur-
rence.29 To ensure the safety of BAY 94-8862 and its proposed
dosing in ARTS, patients with HFREF and mild CKD (part A)
were evaluated and monitored by the DMC before patients with
HFREF and moderate CKD were entered into the study (part B).
In ARTS, renal effects of BAY 94-8862 are monitored by several
parameters including serum creatinine, eGFR, the urinary albumin:-
creatinine ratio, and exploratory biomarkers of renal injury, such as
NGAL and KIM-1. Effects on cardiac function and injury will also be
assessed by monitoring the concentrations of various biomarkers
including BNP, NT-proBNP, and ultrasensitive troponin I. The dur-
ation of the treatment period (4 weeks) and the follow-up after
termination of study medication (14 days) should allow an assess-
ment of the optimal effectiveness of BAY 94-8862 on the MR.
In addition to assessing safety and effects on markers of
end-organ function and injury, ARTS will provide information on
the pharmacokinetic properties of BAY 94-8862 and its optimal
dosing in patients with HFREF and CKD. The study has been
designed to determine doses of BAY 94-8862 that cause a signifi-
cantly lower increase in serum potassium and incidence of hyper-
kalaemia than spironolactone (25–50 mg o.d.), while having
significantly greater efficacy than placebo and at least similar
efficacy to spironolactone, as assessed by levels of BNP or
NT-proBNP, ultrasensitive troponin I, ADMA, galectin-3, and
osteopontin. The relative potency at the MR may be assessed indir-
ectly by measuring the changes in aldosterone levels. In patients
with HFREF and CKD, these biomarkers should provide initial
insight into the relative effects of BAY 94-8862 on collagen forma-
tion, ventricular remodelling, and nitric oxide availability, all of
which have been associated with cardiovascular mortality in
patients with HFREF and/or CKD.
Conclusion
Heart failure remains a highly prevalent disease with high mortality
despite current treatment. The presently available steroidal MRAs
spironolactone and eplerenone have been shown to improve out-
comes, but adverse effects and the need for frequent monitoring of
serum potassium and renal function throughout treatment have
limited their uptake in routine clinical practice. Several potential
new indications for MRAs are yet to be systematically investigated.
BAY 94-8862 is a novel non-steroidal MRA that could potentially
combine high potency (similar to spironolactone) with high select-
ivity (greater than eplerenone), improved end-organ protective
activity, and improved safety compared with previous MRAs,
based on differences in physicochemical properties. ARTS—a mul-
ticentre, randomized, double-blind, placebo-controlled study—is
the first clinical trial of BAY 94-8862 in patients and is expected
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to provide a wealth of information on BAY 94-8862 in individuals
with HFREF and CKD. Should the hypothesis prove correct and
BAY 94-8862 is demonstrated to have improved safety at a given
efficacy than presently available steroidal MRAs in these high-risk
patients with HFREF and moderate CKD, this would open the
way for larger clinical outcome studies in this patient group and
possibly other indications, potentially leading to reductions in
cardiovascular mortality, hospitalizations for HF, and healthcare
resource use.
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